Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | EP300 | Q09472 | 1/20 | 0.34 |
| ▸ | BCDIN3D | Q7Z5W3 | 3/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.33 |
| ▸ | P2RX2 | Q9UBL9 | 5/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | FLT1 | P17948 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27808347 | 0.81 | DAO (0.38) | DAOEP300BCDIN3DP2RX3P2RX2 | |
| SCHEMBL265830 | 0.74 | HRH3 (0.48) | DAOMAPTCYP3A4CYP3A5 | |
| SCHEMBL264967 | 0.73 | MAPT (0.53) | TP53MAPTCYP3A4 | |
| SCHEMBL265381 | 0.72 | SMN1; SMN2 (0.45) | DAOTP53 | |
| SCHEMBL265097 | 0.72 | MAPT (0.50) | DAOMAPTCYP3A4CYP3A5 | |
| SCHEMBL264961 | 0.72 | DAO (0.41) | DAONAMPTKDM1AMAOAMAOB | |
| SCHEMBL263388 | 0.71 | MAPT (0.43) | DAOTP53MAPTCYP3A4 | |
| SCHEMBL271864 | 0.71 | DAO (0.43) | DAONAMPTKDM1AMAOAMAOB | |
| SCHEMBL267315 | 0.70 | TRPV1 (0.54) | DAOMAPTFLT1KDR | |
| SCHEMBL272264 | 0.69 | DAO (0.42) | DAOEP300KDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133909-B2 | Heteroaromatic monoamides as orexinin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20090312314-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312314-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | DAO 1311/4885EP300 1636/4885BCDIN3D 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.